

May 13, 2025

BSE Limited

P. J. Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Dear Sir,

Subject: Outcome of Board Meeting held on May 13, 2025.

Ref: ISIN: INE837H01020

With reference to the notice of Board Meeting dated May 06, 2025, we hereby inform that the Board of Directors at its Meeting held on May 13, 2025 (commenced at 11:10 a.m. and concluded at 12:10 p.m.) has *inter alia*, transacted the following business:

- Approved the Annual Financial Statements (Standalone and Consolidated) of the Company for the financial year ended March 31, 2025 along with fourth quarter results.
- Recommended a Final Dividend @ 60% i.e. ₹ 1.20/- per Equity Share on the face value of ₹ 2/- each for the financial year 2024-25, subject to the approval of the Shareholders at the ensuing 36th Annual General Meeting of the Company ("AGM").

Pursuant to Regulation 42 of Listing Regulations, the record date to determine the shareholders who will be eligible to receive the final dividend, subject to shareholder's approval, will be Wednesday, July 23, 2025.

The Final Dividend, if approved / declared by the Shareholders at 36th AGM, will be paid on and from the second day from the date of AGM.

- The 36th Annual general Meeting of the Company will be held on July 30, 2025 through Video Conferencing and Other Audio-Visual Means in accordance with General Circular No. 09/2024 dated September 19, 2024, issued by Ministry of Corporate Affairs, in continuation to the Circulars issued earlier in this regard.
- Declared an Interim Dividend @ 200% i.e. ₹ 4 per Equity Share on the face value of ₹ 2/- each for the financial year 2025-26. The Interim Dividend for Financial Year 2025-26 will be paid to those shareholders whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares determined with reference to the Record Date of May 17, 2025 (Saturday), already announced for the said purpose by the Company vide letter dated May 06, 2025. The aforesaid Interim Dividend will be paid to the Shareholders on or before June 10, 2025.

Advanced Enzyme Technologies Ltd.

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

- Approved the incorporation of a private company as the wholly-owned subsidiary in India, as per the brief details enclosed.
- Approved the appointment of Mr. Shiv Hari Jalan, Proprietor of M/s. Shiv Hari Jalan & Co., Company Secretaries in Practice (C.P. No. 4226) as the Secretarial Auditors of the Company for a period of five consecutive years commencing from the conclusion of the ensuing AGM till the conclusion of 41st AGM subject to the approval of shareholders at the ensuing Annual general Meeting.

In view of the aforesaid, the following are enclosed:

- Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 signed by Mr. Mukund Kabra, Whole-time Director of the Company - Annexure I;
- Audited Financial Statements (Standalone & Consolidated) the financial year ended March 31, 2025 including quarterly results along with the Auditor's Report issued by MSKA & Associates, Statutory Auditors of the Company - Annexure II;
- Details with respect to the incorporation of Wholly Owned Subsidiary as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI circular number SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 - Annexure III.
- Brief details pertaining to the appointment of Secretarial Auditors – Annexure IV.

The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com

This is for your information and for public at large.

Thanking you,
Yours faithfully,

For Advanced Enzyme Technologies Limited



Sanjay Basantani
Company Secretary and Head – Legal
Encl.: As above



Advanced Enzyme Technologies Ltd.

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

Annexure I

Date : May 13, 2025

BSE Limited

P. J. Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1,
G Block Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Dear Sir,

Subject: Declaration with respect to Audit Report with unmodified opinion

We hereby declare that the Audited Financial Statements for the financial year ended March 31, 2025, which have been approved by the Board of Directors at their meeting held today i.e: May 13, 2025, MSKA & Associates, Statutory Auditors of the Company have issued Auditors' Report with an unmodified opinion on the financial statements.

This declaration is made pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

Thanking you,

Yours Faithfully,

For Advanced Enzyme Technologies Limited

M. W. Kabra

Mukund Kabra

Whole-time Director
00148294



Independent Auditor's Report on Consolidated Audited Annual Financial Results of the Group pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of Advanced Enzyme Technologies Limited

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Annual Financial Results of Advanced Enzyme Technologies Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on Separate Audited Financial Statements of the subsidiaries, the aforesaid Statement:

(i) includes the Annual Financial Results of Holding Company and the following entities

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Advanced Bio-Agro Tech Limited	Subsidiary
2	Advanced Enzytech Solutions Limited	Wholly owned subsidiary
3	Advanced Enzymes USA, Inc. ('AEU')	Wholly owned subsidiary
4	Advanced Supplementary Technologies Corporation	Wholly owned subsidiary of AEU
5	Cal India Foods International ('CAL')	Wholly owned subsidiary of AEU
6	Enzyme Innovation, Inc	Wholly owned subsidiary of CAL
7	Starya Labs, Inc.	Wholly owned subsidiary of AEU (incorporated on December 9, 2024)
8	JC Biotech Private Limited	Subsidiary
9	Scitech Specialities Private Limited	Subsidiary
10	Advanced Enzymes Europe B.V. ('AEEBV')	Wholly owned subsidiary
11	Evoxx Technologies GmbH	Wholly owned subsidiary of AEEBV
12	Saiganesh Enzytech Solutions Private Limited	Subsidiary



(ii) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Group, for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Consolidated Financial Results

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared on the basis of the Consolidated Annual Financial Statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in accordance with the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group and of or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditors' Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to Consolidated Financial Statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



MSKA & Associates

Chartered Accountants

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters:

1. The Statement includes the Audited Financial Results of twelve subsidiaries, whose Financial Results reflect Group's share of total assets of Rs. 11,994.86 million as at March 31, 2025, Group's share of total revenue of Rs. 4,586.23 million, Group's share of total net profit after tax of Rs. 892.87 million, and the Group's share of total comprehensive income of Rs. 1,097.61 million for the period from April 1, 2024 to March 31, 2025, and Group's net cash outflow of Rs. (236.35) million for the year ended as on date respectively, as considered in the Statement, which have been audited by the other auditors whose reports on Financial Statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Subsidiaries is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.

Our opinion is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

2. Seven subsidiaries are located outside India whose Financial Statements have been prepared in accordance with the accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's Management has converted the Financial Statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India.

These conversion adjustments have been audited by another auditors. Our opinion on the Statement, in so far as it relates to the Financial Statements of such subsidiaries, located outside India is based on the report of other auditors and the conversion adjustments prepared by the Management of the Holding Company and audited by another auditors.

Our opinion is not modified in respect of the above matter.



MSKA & Associates

Chartered Accountants

3. The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Amrisha Vaidya

Partner

Membership No.: 101739

UDIN: 25101739B MIKFB5878



Place: Mumbai

Date: May 13, 2025

Statement of audited consolidated financial results for the quarter and year ended 31 March 2025

Particulars	Quarter ended			Year ended	
	31-Mar-25 Audited (Refer note xiv)	31-Dec-24 Unaudited	31-Mar-24 Audited (Refer note xiv)	31-Mar-25 Audited	31-Mar-24 Audited
1 Revenue from operations	1,671.79	1,691.12	1,578.15	6,369.10	6,238.68
2 Other Income	87.45	76.85	94.99	330.41	366.64
3 Total Income (1+2)	1,759.24	1,767.97	1,673.14	6,699.51	6,605.32
4 Expenses					
(a) Cost of materials consumed	459.42	367.64	359.00	1,619.56	1,554.50
(b) Purchases of stock-in-trade #	-	-	0.00	-	0.20
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1.45	20.70	(3.81)	(100.95)	(108.91)
(d) Employee benefits expense (refer note viii & x)	368.37	345.23	329.41	1,415.42	1,277.84
(e) Finance costs (including exchange difference)	8.11	9.43	8.49	35.57	29.28
(f) Depreciation and amortisation expense	100.76	89.73	92.76	365.56	352.42
(g) Other expenses	386.53	405.03	339.87	1,490.71	1,470.46
Total Expenses	1,324.64	1,237.76	1,125.72	4,825.87	4,575.79
5 Profit before exceptional item and tax (3-4)	434.60	530.21	547.42	1,873.64	2,029.53
6 Exceptional item (refer note vi)	-	-	151.32	-	151.32
7 Profit before tax (5-6)	434.60	530.21	396.10	1,873.64	1,878.21
8 Tax expense					
Current tax	141.48	138.21	131.41	495.33	562.00
Deferred tax charge / (credit)	25.84	3.24	(34.03)	38.57	(53.30)
Total tax expense	167.32	141.45	97.38	533.90	508.70
9 Net profit for the period (7-8)	267.28	388.76	298.72	1,339.74	1,369.51
10 Other comprehensive income					
A (i) Items that will not be reclassified to profit or loss					
Remeasurements of defined benefit liability/(asset)	(3.92)	(0.93)	(1.22)	(6.78)	(2.40)
(ii) Income tax related to items that will not be reclassified to profit or loss	0.97	0.26	0.25	1.77	0.58
B (i) Items that will be reclassified to profit or loss					
Exchange differences in translating financial statements of foreign operations	9.54	131.42	11.42	193.23	94.31
(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-	-
Total Other comprehensive income	6.59	130.75	10.45	188.22	92.49
11 Total comprehensive income (9+10)	273.87	519.51	309.17	1,527.96	1,462.00
12 Net profit attributable to:					
Shareholders of the Company	264.82	376.47	283.11	1,311.15	1,333.05
Non-controlling interest	2.46	12.29	15.61	28.59	36.46
13 Other comprehensive income attributable to:					
Shareholders of the Company	6.55	130.78	10.40	188.26	92.53
Non-controlling interest	0.04	(0.03)	0.05	(0.04)	(0.04)
14 Total comprehensive income attributable to:					
Shareholders of the Company	271.37	507.25	293.51	1,499.41	1,425.58
Non-controlling interest	2.50	12.26	15.66	28.55	36.42
15 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.76	223.76	223.65	223.76	223.65
16 Other equity				13,984.87	13,017.63
17 Earnings Per Share of ₹ 2 each (not annualized)					
(a) ₹ (Basic)	2.37	3.36	2.53	11.72	11.92
(b) ₹ (Diluted)	2.37	3.36	2.53	11.71	11.92

Figures are below Rs. 0.01 Million, hence disclosed as Rs. 0.00



Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of audited consolidated assets and liabilities

(₹ in million)

Particulars	As at 31 March 2025	As at 31 March 2024
	Audited	Audited
I. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment	2,929.41	2,765.28
(b) Capital work-in-progress	216.91	307.37
(c) Goodwill	3,334.40	3,252.95
(d) Other Intangible assets	522.91	479.24
(e) Intangible assets under development	0.17	103.62
(f) Financial Assets		
(i) Investments	0.65	1.65
(ii) Loans	0.65	0.38
(ii) Other financial assets	99.19	41.93
(g) Deferred tax assets (net)	101.92	142.82
(h) Income tax assets (net)	177.69	123.31
(i) Other non-current assets	30.88	38.66
Total non-current assets	7,414.78	7,257.21
(2) Current Assets		
(a) Inventories	1,573.05	1,484.55
(b) Financial Assets		
(i) Investments	4,802.58	4,028.50
(ii) Trade receivables	1,153.99	985.68
(iii) Cash and cash equivalents	942.25	1,137.51
(iv) Bank balances other than (iii) above	134.60	131.96
(v) Loans	1.03	1.01
(vi) Other financial assets	80.48	197.20
(c) Income tax asset (net)	-	2.71
(c) Other current assets	110.71	128.30
Total current assets	8,798.69	8,097.42
Total assets	16,213.47	15,354.63
II. EQUITY AND LIABILITIES		
(1) Equity		
(a) Equity share capital	223.76	223.65
(b) Other equity	13,984.87	13,017.63
Equity attributable to the owners of the Company	14,208.63	13,241.28
Non-controlling interest	478.07	469.52
Total equity	14,686.70	13,710.80
(3) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	91.83	69.60
(ii) Lease liability	117.34	158.56
(b) Provisions	13.71	8.86
(c) Deferred tax liabilities (net)	336.34	343.24
Total non-current liabilities	559.22	580.26
(4) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	123.53	181.52
(ii) Lease liability	60.80	63.40
(iii) Trade payables		
a) total outstanding dues of micro enterprises and small enterprises	42.93	32.69
b) total outstanding dues of creditors other than micro enterprises and small enterprises	129.08	124.90
(iv) Other financial Liabilities	266.33	236.99
(b) Other current liabilities	85.28	135.91
(c) Provisions	213.68	196.75
(d) Current tax liabilities (net)	45.92	91.41
Total current liabilities	967.55	1,063.57
Total equity and liabilities	16,213.47	15,354.63



Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India,

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of audited consolidated statement of cashflows

(₹ in million)

	Year ended 31 March 2025 Audited	Year ended 31 March 2024 Audited
A. Cash flows from operating activities		
Profit before tax	1873.64	1878.21
	1873.64	1878.21
Adjustments for non-cash transactions		
Depreciation and amortization expense	365.56	352.42
Prepaid lease amortisation	0.18	0.18
Property, plant and equipments written off	-	0.68
(Profit)/Loss on sale of Property, plant and equipments	(2.17)	2.30
Allowances for bad and doubtful trade receivables	9.25	2.05
Bad and doubtful trade receivables written off	6.43	9.76
Provision for doubtful trade receivables written back	(0.38)	-
Employee stock compensation expense	34.46	30.31
Excess provision written back	(1.98)	(47.67)
Sundry balances written (back)/ off (net)	(0.01)	(1.26)
Fair valuation of investments in marketable securities	(82.25)	(108.48)
Provision for inventory	2.08	-
Provision for investments	1.01	-
Provision for claims and litigations	-	151.32
Unrealized foreign exchange (gain)/ loss	(0.84)	(0.82)
	2,204.98	2,269.00
Items considered separately		
Interest income	(96.72)	(129.72)
Interest expenses	35.75	29.28
Operating profit before working capital changes	2,144.01	2,168.56
Adjustments for:		
(Increase) / Decrease in non-current loans	(0.44)	(1.53)
(Increase) / Decrease in other non-current financial assets	(1.27)	(2.76)
(Increase) / Decrease in other non-current assets	3.02	(10.58)
(Increase) / Decrease in inventories	(77.97)	(238.34)
(Increase) / Decrease in trade receivables	(177.29)	9.12
(Increase) / Decrease in Current loans	(0.02)	0.14
(Increase) / Decrease in financial current assets	113.73	2.12
(Increase) / Decrease in Other current assets	18.20	(20.22)
(Decrease) / Increase in provisions	10.48	40.21
(Decrease) / Increase in trade payables	12.06	(39.41)
(Decrease) / Increase in current financial liabilities - others	9.66	(3.39)
(Decrease) / Increase in other current liabilities	(32.46)	2.11
Cash generated from operating activities	2021.71	1906.03
Income taxes paid (net of refund)	(596.74)	(492.34)
Net cash generated from operating activities	1,424.97	1,413.69
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(338.08)	(423.13)
Proceeds from sale of property, plant and equipments	5.27	1.55
Capital expenditure on intangible assets under development	-	(49.50)
Purchase of intangible assets (net of refund)	(9.73)	(0.50)
(Purchase) / Proceeds from sale of current investments (net)	(590.42)	(276.55)
Interest received	99.43	129.39
(Increase) in bank deposits with maturity more than 3 months but less than 12 months	(1.94)	(27.75)
(Increase) / Decrease in bank deposits with maturity of more than 12 months #	(55.54)	0.00
Net cash generated from investing activities	(891.01)	(646.49)
C. Cash flows from financing activities		
Proceeds from issue of share capital including securities premium	3.78	-
Repayment of long-term borrowings (net)	22.30	(6.48)
Proceed from short-term borrowings (net)	(58.08)	127.03
Transactions with non-controlling interests	-	(56.07)
Interest paid	(33.42)	(29.25)
Lease liability paid	(69.72)	(60.49)
Dividends paid	(590.30)	(567.12)
Net cash (used in) financing activities	(725.44)	(592.38)
Net (decrease) / Increase in cash and cash equivalents (A+B+C)	(191.48)	174.82
Cash and cash equivalents as at the beginning of the year	1137.51	964.20
Effect of exchange rate changes on cash and cash equivalents held	(3.78)	(1.51)
Cash and cash equivalents as at the end of the period	942.25	1,137.51
Composition of cash and cash equivalents		
Cash in hand	0.96	0.52
Cheques in hand	-	5.40
Balance with banks :		
Current account	266.14	414.11
Fixed deposit account (with maturity less than 3 months)	7.65	54.90
Liquid fund balance (with maturity less than 3 months)	667.50	662.58
	942.25	1,137.51

Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00



Notes:

(i) The above audited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Saiganesh Enzytech Solutions Private Limited (India), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Starya Labs, Inc. (w.e.f. 09 December 2024), Advanced Enzymes (Malaysia) Sdn. Bhd. (Malaysia) (up to 08 November 2023), Advanced Enzymes Europe B.V. (Netherlands) and Evovx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".

(ii) The above audited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 13 May 2025. The above results have been audited by the statutory auditors of the Company and they have expressed an unmodified opinion. The audit report will be filed with stock exchanges and will be available on the Company's website. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India.

(iii) On 05 March 2024, the Company had acquired additional stake of 5.89% in its subsidiary JC Biotech Private Limited for consideration of Rs. 56.07 million. Post this additional acquisition the Company holds 95.72% stake in the subsidiary. On account of acquisition of additional stake of 5.89% by the Company in JC Biotech Private Limited Non-controlling interest was reduced by Rs. 49.90 million and Rs. 6.17 million was adjusted in other equity. Impact of additional stake of 5.89% acquired in subsidiary JC Biotech Private Limited as on the date of acquisition of the additional stake is summarised as below-

Particulars	Rs. in million
(A) Consideration paid to acquire additional 5.89% stake	56.07
(B) Value of 5.89% non-controlling interest acquired	49.90
(C) Adjusted in other equity (A-B)	6.17

(iv) On 01 April 2023, the Group completed the acquisition of Shri Ganesh Industrial Enzymes (a partnership firm based in Burhanpur, Madhya Pradesh) ("SGIE"), through a slump sale for a total consideration of Rs. 9.00 million. The Group on finalising of purchase price allocation has recognised fair value of Net Assets acquired of Rs. 5.71 million resulting in Goodwill of Rs. 3.29 million.

(v) On 08 November 2023, Advanced Enzymes (Malaysia) Sdn. Bhd. (Malaysia) the wholly owned subsidiary of the Company got dissolved and ceased to be the subsidiary.

(vi) The District of Arizona (U.S.A.) pronounced an order in respect of lawsuit filed by a competitor against the Advanced Supplementary Technologies Corporation (U.S.A.) ("AST") wholly owned subsidiary of Advanced Enzymes USA, Inc. (U.S.A.) dated 27 February 2024. The Honorable Court after considering the counter claim by AST issued net monetary judgement in favor of the competitor for Rs. 151.32 million this has been accounted in the quarter ended 31 March 2024.

(vii) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(viii) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board.

(ix) The Group has allotted 57,075 equity shares during the year ended 31 March 2025 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(x) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(xi) On 19 December 2024, the Company invested Rs. 478.18 million in Advanced Enzymes Europe B.V. ("AEEBV") (wholly owned subsidiary) by way of subscription to 3,623,163 equity shares. The value per equity share is EUR 1.48 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 7,900,000 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

(xii) Effective date 07 April 2023, loan given by the Company to Advanced Enzymes Europe B.V. (AEEBV) including the outstanding interest aggregating to Rs. 329 million got converted into 2,276,837 fully paid up equity shares. The value per equity share is EUR 1.63 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 4,276,837 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

(xiii) Effective date 01 April 2023, Advanced Supplementary Technologies Corporation (U.S.A.) and Dynamic Enzymes, Inc. (U.S.A.) wholly owned subsidiaries of Advanced Enzymes USA, Inc. (U.S.A.) merged. As a result of merger, Dynamic Enzymes, Inc. (U.S.A.) has been merged with Advanced Supplementary Technologies Corporation (U.S.A.) and Dynamic Enzymes, Inc. (U.S.A.) has ceased to exist.

(xiv) The figures for the quarter ended 31 March 2025 and the corresponding quarter ended in previous year as reported in these consolidated financial results are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

(xv) The Board of Directors of the Company declared interim dividend of Rs. 4/- per equity share. The record date for the payment is 17 May 2025. The interim dividend will be paid on or before 10 June 2025.

(xvi) The Board of Directors in its meeting held on 13 May 2025 have proposed the final dividend for the financial year 2024-25 of Rs. 1.20/- per equity share and the same will be paid after approval of the shareholders of the Company in its Annual General Meeting.

(xvii) Previous period's figures have been regrouped / reclassified where necessary, to conform to the current period's classification.



Place: Thane
Dated: 13 May 2025

By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018

W. M. Kabra

M.M. Kabra
Wholetime Director
DIN : 00148294



Independent Auditor's Report on Standalone Audited Annual Financial Results of the Advanced Enzyme Technologies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of Advanced Enzyme Technologies Limited

Report on the Audit of Standalone Financial Results

Opinion

We have audited the accompanying statement of Standalone Annual Financial Results of **Advanced Enzyme Technologies Limited** (hereinafter referred to as 'the Company') for the year ended March 31, 2025 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Management's and Board of Directors' Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the Standalone Annual Financial Statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended, issued thereunder and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the financial reporting process of the Company.

Auditors' Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to Standalone Financial Statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



MSKA & Associates

Chartered Accountants

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters:


The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Amrisha Vaidya

Partner

Membership No. 101739

UDIN: 25101739BM IKFA1303



Place: Mumbai

Date: May 13, 2025

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of audited standalone financial results for the quarter and year ended 31 March 2025

Particulars	Quarter ended			Year ended	
	31-Mar-25 Audited (refer note vii)	31-Dec-24 Unaudited	31-Mar-24 Audited (refer note vii)	31-Mar-25 Audited	31-Mar-24 Audited
1 Revenue from operations	872.06	1,008.70	924.03	3,514.11	3,654.69
2 Other Income	45.30	14.29	32.10	614.90	588.09
3 Total Income (1+2)	917.36	1,022.99	956.13	4,129.01	4,242.78
4 Expenses					
(a) Cost of materials consumed	377.92	362.56	334.45	1,488.00	1,395.61
(b) Purchases of stock-in-trade	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3.99	73.54	(19.46)	(64.67)	(78.34)
(d) Employee benefits expense (refer note iii and v)	145.59	133.39	133.91	560.35	493.88
(e) Finance costs (including exchange difference)	0.77	0.61	0.48	2.36	1.57
(f) Depreciation and amortisation expense	31.14	28.88	30.67	114.05	108.98
(g) Other expenses	202.86	218.59	182.69	823.64	791.68
Total expenses	762.27	817.57	662.74	2,923.73	2,713.38
5 Profit before exceptional item and tax (3-4)	155.09	205.42	293.39	1,205.28	1,529.40
6 Exceptional item (refer note x)	-	-	189.48	-	189.48
7 Profit before tax (5-6)	155.09	205.42	103.91	1,205.28	1,339.92
8 Tax expense					
Current tax	35.45	53.29	75.36	168.86	269.51
Deferred tax charge/(credit)	9.10	0.29	(2.83)	12.22	(10.82)
Total tax expense	44.55	53.58	72.53	181.08	258.69
9 Net profit for the period (7-8)	110.54	151.84	31.38	1,024.20	1,081.23
10 Other comprehensive income					
A (i) Items that will not be reclassified to Profit or Loss					
Remeasurements of defined benefit liability/(asset)	(4.60)	-	(1.38)	(4.60)	(1.38)
(ii) Income tax related to items that will not be reclassified to Profit or Loss	1.16	-	0.35	1.16	0.35
B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-
(ii) Income tax related to items that will be reclassified to Profit or Loss	-	-	-	-	-
Total Other comprehensive income	(3.44)	-	(1.03)	(3.44)	(1.03)
11 Total comprehensive income (9+10)	107.10	151.84	30.35	1,020.76	1,080.20
12 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.76	223.76	223.65	223.76	223.65
13 Other equity				6,069.65	5,581.06
14 Earnings Per Share of ₹ 2 each (not annualized)					
(a) ₹ (Basic)	0.99	1.36	0.28	9.16	9.67
(b) ₹ (Diluted)	0.99	1.35	0.28	9.15	9.66



Statement of standalone assets and liabilities

		(₹ in million)	
Particulars	As at 31 March 2025 Audited	As at 31 March 2024 Audited	
I. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment	1,508.82	1,418.21	
(b) Capital work-in-progress	207.35	164.45	
(c) Other Intangible assets	56.18	3.10	
(d) Intangible assets under development	0.17	54.12	
(e) Financial Assets			
(i) Investments			
- Investment in subsidiaries	2,536.50	2,054.26	
- other investment	0.62	0.62	
(ii) Loans	0.65	0.37	
(iii) Other financial assets	79.26	22.45	
(f) Income tax asset (net)	160.00	113.44	
(g) Other non-current assets	14.77	14.91	
Total non-current assets	4,564.32	3,845.93	
(2) Current Assets			
(a) Inventories	1,014.50	968.84	
(b) Financial Assets			
(i) Investments	366.52	508.02	
(ii) Trade receivables	781.69	751.72	
(iii) Cash and cash equivalents	56.04	14.95	
(iv) Bank balances other than (iii) above	2.28	5.22	
(v) Loans	0.26	0.42	
(vi) Other financial assets	48.81	172.59	
(c) Other current assets	51.89	61.64	
Total current assets	2,321.99	2,483.40	
Total assets	6,886.31	6,329.33	
II. EQUITY AND LIABILITIES			
(1) Equity			
(a) Equity share capital	223.76	223.65	
(b) Other equity	6,069.65	5,581.06	
Total equity	6,293.41	5,804.71	
(2) Non-current liabilities			
(a) Financial liabilities			
(i) Lease liability	19.69	10.93	
(b) Provisions	8.20	6.61	
(c) Deferred tax liabilities (net)	118.00	106.94	
Total non-current liabilities	145.89	124.48	
(3) Current liabilities			
(a) Financial liabilities			
(i) Lease liability	7.95	4.11	
(ii) Trade payables			
a) total outstanding dues of micro enterprises and small enterprises	33.30	18.91	
b) total outstanding dues of creditors other than micro enterprises and small enterprises	193.46	198.33	
(iii) Other financial Liabilities	134.89	120.08	
(b) Other current liabilities	39.13	30.41	
(c) Provisions	35.36	25.41	
(d) Current tax liabilities (net)	2.92	2.89	
Total current liabilities	447.01	400.14	
Total equity and liabilities	6,886.31	6,329.33	



Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

STATEMENT OF STANDALONE CASH FLOW

	Year ended 31 March 2025 Rs. in million Audited	Year ended 31 March 2024 Rs. in million Audited
A. Cash flows from operating activities		
Profit before tax	1,205.28	1,339.92
	<u>1,205.28</u>	<u>1,339.92</u>
Adjustments for non-cash transactions		
Depreciation and amortization expense	114.04	108.98
Property, plant and equipment written off	-	0.68
(Profit) / Loss on sale of property, plant and equipment	(0.59)	(0.14)
Bad debts written off	4.91	4.32
Provision for doubtful trade receivables provided / (written back)	6.27	(1.30)
Employee stock compensation expense	30.41	25.83
Excess provision written back	(1.98)	(7.14)
Sundry balances written (back) (net)	(0.01)	0.56
Unrealized foreign exchange (gain)	(0.84)	(0.77)
Fair value adjustment on investments	(19.20)	(20.08)
Provision for investments and loans given to subsidiary	-	189.48
	<u>1,338.29</u>	<u>1,640.34</u>
Items considered separately		
Interest income	(11.26)	(11.16)
Interest expenses	2.36	1.57
Dividend income	(561.06)	(526.71)
Operating profit before working capital changes	<u>768.33</u>	<u>1,104.04</u>
Adjustments for working capital changes		
(Increase) / Decrease in Non-current loans	-	(0.19)
(Increase) / Decrease in Other non-current financial assets	(1.27)	(2.76)
(Increase) / Decrease in other non-current assets	(0.33)	(1.64)
(Increase) / Decrease in inventories	(45.66)	(200.96)
(Increase) / Decrease in trade receivables	(40.62)	(87.24)
(Increase) / Decrease in Current loans	0.16	(0.01)
(Increase) / Decrease in other current financial assets	120.83	(41.58)
(Increase) / Decrease in Other current assets	9.75	(15.45)
(Decrease) / Increase in provisions	6.95	7.61
(Decrease) / Increase in trade payables	11.82	42.47
(Decrease) / Increase in other current financial liabilities	11.55	(10.11)
(Decrease) / Increase in other current liabilities	8.73	(5.82)
Cash generated from operating activities	<u>850.24</u>	<u>788.36</u>
Income taxes paid (net)	(215.45)	(272.06)
Net cash generated from operating activities	<u>634.79</u>	<u>516.30</u>
B. Cash flows from investing activities		
Purchase of property, plant and equipment (tangible assets)	(223.37)	(206.12)
Proceeds from sale of property, plant and equipment	1.21	1.30
Purchase of intangible assets (net of refunds)	(0.83)	(0.25)
Purchase of non-current investments	(478.18)	(56.07)
(Purchase) / Proceeds from sale of current investments (net)	160.71	(328.05)
Interest received	13.93	11.20
Dividend received	561.06	526.71
(Increase) / Decrease in bank deposits with maturity more than 3 months but less than 12 months	3.63	24.25
(Increase) / Decrease in bank deposits with maturity of more than 12 months #	(55.54)	(0.00)
Net cash generated in investing activities	<u>(17.38)</u>	<u>(27.03)</u>
C. Cash flows from financing activities		
Proceeds from issue of share capital including securities premium	3.78	-
Repayment of short-term borrowings (net) #	-	(0.07)
Interest paid	(0.02)	(1.57)
Payment of Lease liabilities	(9.78)	(8.05)
Dividends paid	(570.30)	(559.12)
Net cash (used in) financing activities	<u>(576.32)</u>	<u>(568.81)</u>
Net (decrease) / increase in cash and cash equivalents (A+B+C)	41.09	(79.54)
Cash and cash equivalents as at the beginning of the period	14.95	94.49
Effect of exchange rate changes on cash and cash equivalents held	-	-
Cash and cash equivalents as at the end of the period	<u>56.04</u>	<u>14.95</u>
Composition of cash and cash equivalents		
Cash in hand	0.40	0.31
Balance with banks :		
Current account	52.48	14.64
Fixed deposit account (with maturity less than 3 months)	3.16	-
	<u>56.04</u>	<u>14.95</u>

Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00



Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No: 91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above standalone financial results of Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 13 May 2025. The above results have been audited by the statutory auditors of the Company and they have expressed an unmodified opinion. The audit report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India.

(ii) The Company operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iii) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board.

(iv) The Company has allotted 57,075 equity shares during the year ended 31 March 2025 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(v) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(vi) On 19 December 2024, the Company invested Rs 478.18 million in Advanced Enzymes Europe B.V. ('AEEBV') (wholly owned subsidiary) by way of subscription to 3,623,163 equity shares. The value per equity share is EUR 1.48 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 7,900,000 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

(vii) The figures for the quarter ended 31 March 2025 and the corresponding quarter ended in previous year as reported in these standalone financial results are the balancing figures between standalone audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

(viii) The Board of Directors of the Company declared interim dividend of Rs 4/- per equity share. The record date for the payment is 17 May 2025. The interim dividend will be paid on or before 10 June 2025.

(ix) The Board of Directors in its meeting held on 13 May 2025 have proposed the final dividend for the financial year 2024-25 of Rs 1.20/- per equity share and the same will be paid after approval of the shareholders of the Company in its Annual General Meeting.

(x) During the annual audit for the financial year 2023-24, the company conducted a fair value assessment of its investment in Advanced Enzymes Europe B.V. (AEEBV). This assessment considered past business performance, current business conditions and revised future performance expectations. As a result, an impairment loss of Rs. 189.48 million was recognized for the investment in the subsidiary.

(xi) Previous year / period amounts have been regrouped / reclassified wherever necessary.

By Order of the Board of Directors

For Advanced Enzyme Technologies Limited

CIN: L24200MH1989PLC051018

M. M. Kabra

M. M. Kabra

Wholtime Director

DIN : 00148294

Place: Thane

Dated: 13 May 2025



Annexure III

Brief details pertaining to the incorporation of a private company as a wholly-owned subsidiary of the Company:

Sr. No.	Particulars	Details
I.	Name of the entity, date & country of incorporation, etc.	The name of the proposed Wholly Owned Subsidiary (private company) will be such as may be applied and approved by the Registrar of Companies; Date - The private company is yet to be incorporated; Country of Incorporation – To be incorporated in India
II.	Name of holding company of the incorporated company and relation with the listed entity	Advanced Enzyme Technologies Limited; and the proposed new company to be incorporated as its wholly-owned Subsidiary
III.	Industry to which the entity being incorporated belongs	Nutrition and Wellness
IV.	Brief background about the entity incorporated in terms of products / line of business	The proposed company will carry on the business of sales and distribution of the holding company's range of products.
V.	Brief details of any governmental or regulatory approvals required for the incorporation	No governmental or regulatory approval is required.
VI.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
VII.	Cost of subscription / price at which the shares are subscribed	The Company to subscribe to upto 50,000 Equity shares at face value of ₹ 10 per Equity share, in the proposed wholly owned subsidiary
VIII.	Percentage of shareholding / control by the listed entity and / or number of shares allotted	100 %



Advanced Enzyme Technologies Ltd.

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

Annexure IV

Brief details pertaining to the appointment of the Secretarial Auditors of the Company:

Sr. No.	Particulars	Secretarial Auditors
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Mr. Shiv Hari Jalan, Proprietor of M/s. Shiv Hari Jalan & Co., Company Secretaries in Practice (C.P. No. 4226) as the Secretarial Auditors of the Company.
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	May 13, 2025; Term - for a period of five consecutive years commencing from the conclusion of the ensuing AGM till the conclusion of 41st AGM subject to approval of Shareholders at the ensuing Annual General Meeting.
3.	Brief profile (in case of appointment);	M/s. Shiv Hari Jalan & Co., founded by Mr. Shiv Hari Jalan, has distinguished exposure and over thirty eight years of experience in compliance audit, compliance management system, legal due diligence, vetting of various legal agreements, private equity, public offerings, preparation of business plans, Secretarial Audit etc.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

